KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Tax Provisions: 2017-2025

Historic Tax Provisions for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to -$23.4 million.

  • Amneal Pharmaceuticals' Tax Provisions fell 737.07% to -$23.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 52.62%. This contributed to the annual value of $18.9 million for FY2024, which is 122.35% up from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Tax Provisions stood at -$23.4 million, which was down 245.05% from $16.1 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Tax Provisions ranged from a high of $16.1 million in Q2 2025 and a low of -$23.4 million during Q3 2025.
  • In the last 3 years, Amneal Pharmaceuticals' Tax Provisions had a median value of $3.7 million in 2024 and averaged $3.0 million.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Tax Provisions tumbled by 975.00% in 2022 and then soared by 15,830.43% in 2024.
  • Over the past 5 years, Amneal Pharmaceuticals' Tax Provisions (Quarterly) stood at $4.1 million in 2021, then tumbled by 143.90% to -$1.8 million in 2022, then soared by 651.72% to $9.9 million in 2023, then plummeted by 45.02% to $5.5 million in 2024, then plummeted by 737.07% to -$23.4 million in 2025.
  • Its last three reported values are -$23.4 million in Q3 2025, $16.1 million for Q2 2025, and $12.9 million during Q1 2025.